AMRX NASDAQ
Amneal Pharmaceuticals, Inc.
1W: +8.1%
1M: +4.6%
3M: +12.2%
YTD: +69.3%
1Y: +103.2%
3Y: +517.9%
5Y: +278.1%
$21.44
+0.42 (+2.00%)
Pre-Market: $21.83 (+0.39, +1.82%)
Weekly Expected Move ±4.0%
$19
$20
$20
$21
$22
Credit Risk of going bust: lower than 58% of companies Debt: 29.0% of company value Bonds: $58.6M held by 128 funds, 178 bp over Treasuries → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.60 (down 97%), Amneal Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $2.79B against a stock market value of $6.85B.
Distance to default 5.94 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.39B (short-term plus half of long-term), stock volatility 35.6%; Altman Z 2.53. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $0.60 (down 97%), Amneal Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $2.79B against a stock market value of $6.85B.
Distance to default 5.94 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.39B (short-term plus half of long-term), stock volatility 35.6%; Altman Z 2.53. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.67
Bullish
3 bullish
1 neutral
0 bearish
Articles (24h)
4
Hourly Sentiment (24h)
0.75
Bullish
5 bullish
1 neutral
0 bearish
Articles (7d)
6
Daily Sentiment (7 Days)
Articles (100)
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
Implied Volatility Surging for Amneal Pharmaceuticals Stock Options
30,437 Shares of Amneal Pharmaceuticals, Inc. $AMRX Bought by Gibbs Wealth Management
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Has Consensus Target Price of $21.00
741,577 Amneal Pharmaceuticals, Inc. $AMRX Shares Acquired by Congress Asset Management Co.
Oppenheimer's fall 2026 SMID-cap ideas include four Strong Buy stocks
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Has Consensus Price Target of $21.00
Corient Private Wealth LP Boosts Holdings in Amneal Pharmaceuticals, Inc. $AMRX
Why Is Amneal (AMRX) Stock Rocketing Higher Today - StockStory
How Investors May Respond To Amneal Pharmaceuticals (AMRX) FDA Approval Launch - simplywall.st
AMRX Stock Advances As Generic To Ipsen’s Hormone Shot Gets FDA Nod - Stocktwits
An injection for three conditions launches immediately after FDA approval - Stock Titan
Amneal Announces FDA Approval and Launch of Lanreotide Injection
Amneal Announces FDA Approval and Launch of Lanreotide Injection
3 Reasons to Avoid AMRX and 1 Stock to Buy Instead
3 Reasons to Avoid AMRX and 1 Stock to Buy Instead - Yahoo Finance
Looming biosimilar void risks $189B in lost U.S. healthcare savings: report
Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains? - Yahoo Finance
Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?
Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?
Amneal Pharmaceuticals Inc (AMRX) Stock Down 3.3% but Still Over - GuruFocus
Does Amneal’s Post‑Earnings Shelf Registration Reshape the Bull Case for Amneal Pharmaceuticals (AMRX)?
Does Amneal’s Post‑Earnings Shelf Registration Reshape the Bull Case for Amneal Pharmaceuticals (AMRX)? - Yahoo Finance
Amneal Pharmaceuticals (AMRX) Bets Big On Biosimilars While Wall Street Retreats
Amneal Pharmaceuticals (AMRX) Stock Sees Modest Fair Value Lift On Launch Optimism
Amneal Pharmaceuticals (AMRX) Stock Sees Modest Fair Value Lift On Launch Optimism - Yahoo Finance
Generic Pharmaceuticals Stocks Q2 Results: Benchmarking Amneal (NASDAQ:AMRX)
Generic Pharmaceuticals Stocks Q2 Results: Benchmarking Amneal (NASDAQ:AMRX) - Yahoo Finance
AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study
AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study
BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program
JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis
1 Stock Under $50 with Solid Fundamentals and 2 Facing Challenges
RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy
RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy
Here's Why You Should Add ACET Stock to Your Portfolio Now
Here's Why You Should Add ACET Stock to Your Portfolio Now
Acadia Gets European Commission Nod for Daybu in Rett Syndrome
Acadia Gets European Commission Nod for Daybu in Rett Syndrome
Are Medical Stocks Lagging Bioventus (BVS) This Year?
Are Medical Stocks Lagging Bioventus (BVS) This Year?
Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?
Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?
TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette Syndrome
Reasons Why Investors Should Consider Betting on PGEN Stock
RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos
RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win
AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
Zacks.com featured highlights include CareDx, Healthcare Services, Forum Energy Tech, Amneal Pharma and Caterpillar
ARGX Announces Positive Phase III Data on Vyvgart Hytrulo, Stock Up
UTHR Completes Phase III Tyvaso Study Enrollment for Expanded Label
EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal
5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns
Is Amneal Pharmaceuticals (AMRX) Fairly Valued After A 3.5x Return? - Yahoo Finance
Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus
Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus
CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus
Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?
Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?
AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?
BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA
Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist? - Yahoo Finance
KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema
Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why
Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader
Assenagon Asset Management S.A. Has $42.33 Million Stock Position in Amneal Pharmaceuticals, Inc. $AMRX
Amneal (AMRX) Upgraded to Buy: What Does It Mean for the Stock?
Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?
Arkadios Wealth Advisors Takes Position in Amneal Pharmaceuticals, Inc. $AMRX
Amneal (AMRX) Stock Looks About Fair Value On Current Earnings - Yahoo Finance
AMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raised
Amneal Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Compared to Estimates, Amneal (AMRX) Q2 Earnings: A Look at Key Metrics
Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Surpass Estimates
Amneal Reports Second Quarter 2026 Financial Results
Spotting Winners: Amneal (NASDAQ:AMRX) And Generic Pharmaceuticals Stocks In Q1 - Yahoo Finance
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock
Amneal Pharmaceuticals, Inc. $AMRX Shares Acquired by Allspring Global Investments Holdings LLC
Commonwealth of Pennsylvania Public School Empls Retrmt SYS Buys New Stake in Amneal Pharmaceuticals, Inc. $AMRX
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts
3 Reasons AMRX is Risky and 1 Stock to Buy Instead - Yahoo Finance
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
Why Amneal Pharmaceuticals (AMRX) is a Top Momentum Stock for the Long-Term
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?
Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?
AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?
AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Amneal and Pfizer GLP-1 Deal: New Growth Lever?
Is Amneal a Buy Before Rytary Generic Erosion?
What's Driving Amneal's 2026 Growth Outlook?